We assessed the association of vascular endothelial growth factor (VEGF) and nm23 expression with occult micrometastasis in lung cancer. As destination sites for micrometastasis, we scrutinized lymph node (LN) and bone marrow (BM) specimens. For LN, 122 stage I patients who had received curative operations were studied. As regards BM, 203 patients in stage I-IV who underwent operations were registered. Immunohistochemical anti-cytokeratin staining was used to detect microdissemination of cancer cells. The VEGF and the nm23 expression at the primary sites were immunohistochemically studied in 285 cases in total. The percentages of the patients with microdissemination were 28.7% for LN and 42.4% for BM. The outcome for the patients with LN or BM microdissemination was significantly worse than that for patients without it. The increased VEGF and the decreased nm23 expression within primary tumors were significantly associated with LN and BM microdissemination. The results indicate possible value of using these biological markers to predict the risk of systemic micrometastasis in non-small cell lung cancer.
Patients For the assessment of nodal micrometastasis, 122 primary tumors and 2030 lymph nodes (LN) were obtained from primary lung cancer patients in stage I. The 78 men and 44 women with a mean age of 65.0±8.2 years (range, 46 to 84) underwent operations at Kanazawa University Hospital from 1988 to 1991. The pathological types were 77 adenocarcinomas, 37 squamous cell carcinomas, six adenosquamous carcinomas, one large cell carcinoma, and one mucoepidermoid carcinoma. According to TNM classification, 78 patients were T1N0M0 and 44 were T2N0M0. On the other hand, for the assessment of bone marrow micrometastasis, 203 lung cancer patients in various stages (stage I, 110; stage II, 19; stage IIIA, 44; stage IIIB, 27; stage IV, 3) were included in the study. The 139 men and 64 women with a mean age of 65.0±7.0 (range, 25 to 89) underwent operations from 1996 to 1999. Pathological types were 129 adenocarcinomas, 60 squamous cell carcinomas, seven adenosquamous carcinomas, and seven large cell carcinomas. The basic clinical features of the patients are summarized in Table I . Patients gave their informed consent for the use of clinical materials including resected specimens. Immunohistochemistry for the detection of micrometastases To examine nodal micrometastasis, we carried out immunohistochemical staining using anti-cytokeratin antibodies, AE1/AE3 (DAKO, Carpinteria, CA) for LN and CK2 (Boehringer Mannheim Biochemica, Mannheim, Germany) for bone marrow. The paraffin-embedded lymph node samples were sectioned at 4 µm and the sections were floated onto silanized slides. Then the sections were deparaffinized and boiled for 5 min in 0.01 M sodium citrate solution (pH 6.0) in a microwave oven three times. Endogenous peroxidase was blocked by treatment with 0.3% hydrogen peroxide in methanol for 15 min. The sections were incubated with normal goat serum diluted 10-fold with phosphate-buffered saline (PBS) for 15 min at room temperature for blocking. After having been washed with PBS, the sections were reacted with anti-AE1/AE3 antibody (diluted 50-fold with PBS) for 1 h at room temperature. They were then reacted with biotin-labeled goat anti-mouse immunoglobulin (DAKO, CA) for 2 h, and washed with PBS. Avidin-biotin-peroxidase complex was added and color was developed with 3-3′ diaminobenzidine (Sigma, St. Louis, MO) and 0.03% hydrogen peroxide. The cytospin preparations for bone marrow (BM) aspirates were stained by the alkaline phosphatase antialkaline phosphatase method by using a commercial kit (DAKO, Kyoto) according to the procedures recommended by the manufacturer. The sections were reacted with 2 µg/ml of CK2 for 24 h at 4°C. Counterstaining was done with H & E. Taking into consideration morphologic features such as nuclear size, the nucleus-cytoplasmic ratio, and nucleolation, cells that reacted with anti-cytokeratin antibody were considered positive. In this study, both single and clustered tumor cells with a size of not more than 2 mm were defined as micrometastasis.
9, 10) Positivity was evaluated by two independent observers without knowledge of the clinicopathologic factors.
Immunohistochemical assessment of VEGF and nm23
We used consecutive paraffin sections of the invasive edge of the primary tumors, stained immunohistochemically by the labeled streptavidin-biotin method as described above. Primary antibodies used were the anti-VEGF polyclonal antibody (Santa Cruz Biotechnology Inc., Germany) diluted 100-fold and the anti-nm23 monoclonal antibody (DAKO, CA) diluted 50-fold. They were reacted for 2 h at room temperature. The second antibodies used were biotin-labeled goat anti-mouse immunoglobulin (DAKO, CA). The immunoreactivities for VEGF were graded as T1  20  58  25  63  T2  15  29  36  37  T3  --11  8  T4  --14  9  N factor  N0  35  87  40  88  N1  --10  8  N2  --30  20  N3  --6  1  M factor  M0  35  87  84  116  M1  --2 (−), (+), and (+ +) according to the staining intensity of the tumor cells: (−) represents zero or less than 10% positive staining area, (+) represents 10-50% positive staining area, and (+ +) represents more than 50% positive staining area. In this study, we defined a tumor with the strongest stain (+ +) as VEGF-overexpressing. 2, 11) For the assessment of nm23 protein expression, tumors were considered positive if all the epithelial cells in the lesion showed cytoplasmic staining. If any of the epithelial cells were unstained, they were considered negative.
12)
Statistics The association between variables was analyzed by the χ 2 test. Survival curves were obtained by the Kaplan-Meier method, and compared by the log-rank test. The criterion for statistical significance was P<0.05 and the mean values are shown with ±SD.
RESULTS
The detection of cytokeratin-positive tumor cells Positive staining for AE1/AE3 and CK2 was found in all normal epithelial cells and tumor cells in primary sites irrespective of pathologic types. Among 122 patients in stage I, 35 patients (28.7%) had microdissemination of tumor cells within the LN. There were no significant differences in the percentage of the patients with or without nodal microdissemination of cancer cells according to age, gender, pathological type, and T factor. In our series, most of the nodal microdissemination showed clustered tumor cells (Fig. 1A) . On the other hand, the incidence of BM microdissemination was 42.4% (86/203 patients) ( Table I . The expression of VEGF and nm23 in primary sites, and their association with microdissemination VEGF antigens were mainly identified in the cytoplasm of cancer cells and the endothelial cells of vessels alike ( Fig. 2A) . Nm23 antigens were found in the epithelial component and the cytoplasm of cancer cells (Fig. 2B) . Although the VEGF antigen was detected in large amounts in both tumors with nodal microdissemination (88.6%) and those without nodal microdissemination (77.0%, P=0.15), the percentages of patients with the strongest VEGF staining were 68.6% (24/35) in tumors with nodal microdissemination and only 31.0% (27/87) in those without it (P=0.0001). Concerning patients with BM microdissemination, the percentages of the patients with positive and the strongest VEGF staining were 97.1% and 68.1%, respectively, significantly greater as compared to those without BM microdissemination (85.1% and 25.5%, respectively) (P<0.01 and P<0.0001). On the other hand, the nm23 expression was inversely correlated with nodal microdissemination (P=0.008) and with BM microdissemination (P=0.0023). Table II gives an overview of the results. With respect to the diagnosis of nodal microdissemination, the sensitivity and the specificity were 68.6% and 69.0% for VEGF+ +, 80.0% and 46.0% for nm23−, and 62.9% and 81.6% for the combination, VEGF+ + / nm23−, respectively (Table III) . Among the 35 patients with nodal microdissemination, 18 developed recurrence including 15 (83.3%) with VEGF+ + /nm23−. On the other hand, among 64 recurrence-free patients without nodal microdissemination, only 10 (15.6%) had the VEGF+ + /nm23− pattern. Among the patients with nodal microdissemination, the percentage with the VEGF+ + / nm23− pattern was significantly greater as compared to those without microdissemination (P<0.0001) and the VEGF+ + /nm23− pattern was also associated with recurrence in the nodal microdissemination-positive group (P=0.0099) ( Table IV) . As to BM microdissemination, the sensitivity and the specificity were 68.1% and 74.5% for VEGF+ +, 69.6% and 54.3% for nm23−, and 30.4% and 91.5% for VEGF+ + /nm23−, respectively (Table III) . Nodal or BM microdissemination and outcome The 5-year survival rate for the patients with nodal microdissemination was 54.3%, being significantly worse as compared to that (n=87, 75.9%) for the patients without it (P=0.006). Although the follow-up is still too short to allow a definitive conclusion on survival of patients with/ without BM microdissemination, the outcome for the patients with BM microdissemination was significantly worse than that for the patients without it in the assessment of the 157 cases who underwent complete resection of the primary tumor (P<0.0001).
DISCUSSION
Microdissemination of cancer cells in distant organs, such as LN, BM, and peripheral blood circulation, generally results in recurrence even after a curative operation. [13] [14] [15] [16] [17] Therefore adjuvant therapies may be required to inhibit metastasis. In this study, we carried out immunostaining for cytokeratin fragments to examine the microdissemination of cancer cells in LN and BM specimens. To better delineate disseminated tumor cells with/without metastatic capacity, assessment of their biological characteristics including invasive behavior is needed. In a cohort of lung cancer patients, we also studied the expression of the angiogenesis-associated factor, VEGF, and the metastasisassociated factor, nm23, within primary tumors. As a result, we found that the increased expression of VEGF was significantly associated with both nodal and BM microdissemination, together with reduced expression of nm23. These results suggest that neovessels mediated by VEGF are closely associated with the establishment of nodal and BM micrometastasis.
With respect to the association of VEGF to nodal metastasis, we have already confirmed that the VEGF gene expression at primary sites was greater in lung cancer patients with nodal metastasis than in those without it. 18) This finding in non-small cell lung cancer has been supported by other researchers. 19, 20) Non-angiogenic functions of VEGF may also play a role in the development of metastasis. On the other hand, although there are conflicting results, nm23 has been reported to be a putative antimetastatic gene with an inverse correlation to nodal metastasis. [21] [22] [23] In accordance with these previous reports on nodal metastasis diagnosed by conventional methods, negative nm23 expression was also significantly associated with nodal microdissemination and with BM microdissemination in our series. The concurrent analysis of VEGF and nm23 demonstrated that the percentage of patients with VEGF+ + /nm23− pattern was significantly high among patients with nodal microdissemination as compared to patients without it, accounting for 83.3% of the patients with recurrence in the nodal microdissemination-positive group. Although the specificity of nm23 was not high as a marker of nodal or BM microdissemination, VEGF retained high sensitivity and specificity. The VEGF+ + /nm23− pattern appears to be of value especially for the diagnosis of nodal micrometastasis. The evaluation of these markers within tumors may aid the diagnosis of systemic micrometastasis in non-small cell lung cancer. December 14, 2000) 
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